Availability: In StockBiological Description:AB-FUBINACAis an indazole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.1,2 AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.Purity: ≥98%Molecular formula: C₂₀H₂₈N₄O₂Molecular Weight: 129.15Storage Instructions: Two years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSOReferences: for more information, please visit images/AffixScientific/ Affix Scientific的KRN633是一种有效的选择性VEGFR抑制剂。抑制人脐静脉内皮细胞中VEGFR-2的酪氨酸磷酸化（IC50 = 1.16 nmol / L）。用重组酪氨酸激酶进行的选择性分析表明，KRN633对VEGFR-1，-2和-3具有高度选择性。在无胸腺小鼠和大鼠中，KRN633在几种具有不同组织起源的体内肿瘤异种移植模型（包括肺，结肠和前列腺）中抑制肿瘤生长。KRN633还可以使一些公认的肿瘤以及那些在停止治疗后已长出的肿瘤消退。KRN633具有良好的耐受性，对动物的体重或总体健康没有明显影响。KRN633可用于治疗实体瘤和其他依赖病理性血管生成的疾病。